Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 15, 2004. The report details a share repurchase transaction and updates regarding directors' interests in company shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific share buyback transaction:
- Shares Purchased: 420,000 Ordinary shares.
- Purchase Price: 1,180.9821 pence per share.
- Transaction Date: September 14, 2004.
- Treasury Holdings Post-Transaction: 43,293,000 shares.
- Shares in Issue (excluding Treasury): 5,891,277,803 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through a treasury buyback authorized by shareholders at the Annual General Meeting on May 17, 2004. Additionally, the GSK Trust transferred 26,394 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 420,000 share repurchase against the reported price of 1,180.9821 pence.
- Confirm the updated total share count (5,891,277,803 in issue) in subsequent filings.
- Review the impact of the 26,394 shares transferred from the GSK Trust on the Employee Share Option Plan 1991.
- Note that this filing does not contain quarterly or annual financial performance data.